Literature DB >> 17617663

Wayne Fenton's impact on academic neuroscience.

Mark A Geyer1, Carol A Tamminga.   

Abstract

The legacy of Wayne Fenton will undoubtedly include his broad impact upon the academic community of researchers in psychiatry and neuroscience. Although this impact has already been felt, its full breadth and depth can only be anticipated. Eventually, the most profound impact of Wayne Fenton's legacy will likely be the one Wayne most fervently desired: that people with psychiatric disorders receive better and more effective treatments for their illnesses. By virtue of the MATRICS initiative, this impact will begin in the context of treatments for the cognitive deficits in schizophrenia, which is currently a critical unmet need. Within academic settings, this specific impact is already evident as a resurgence of interest in the neurobiology and pharmacology relevant to cognitive dysfunction in schizophrenia. As envisioned by Wayne Fenton, however, the impact of MATRICS and the other programs he initiated will be broader than "only" the treatment of cognitive deficits in schizophrenia. His vision was to target a drug treatment to an individual symptom domain, individualizing treatment regimens for each patient, without requiring a drug to be effective in all domains. Thus, the particular target of opportunity that provided Wayne Fenton's focus in the initiation of the MATRICS program is already having an important impact, but in the longer term these efforts will no doubt lead to parallel developments and improvements in the treatment of other psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617663      PMCID: PMC2632348          DOI: 10.1093/schbul/sbm077

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  12 in total

1.  Medicine. What are the right targets for psychopharmacology?

Authors:  Steven E Hyman; Wayne S Fenton
Journal:  Science       Date:  2003-01-17       Impact factor: 47.728

2.  Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective.

Authors:  Wayne S Fenton; Ellen L Stover; Thomas R Insel
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

3.  A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

Authors:  Robert W Buchanan; Miriam Davis; Donald Goff; Michael F Green; Richard S E Keefe; Andrew C Leon; Keith H Nuechterlein; Thomas Laughren; Robert Levin; Ellen Stover; Wayne Fenton; Steve R Marder
Journal:  Schizophr Bull       Date:  2005-02-16       Impact factor: 9.306

Review 4.  The clinical investigator: bewitched, bothered, and bewildered--but still beloved.

Authors:  J L Goldstein; M S Brown
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

Review 5.  Predicting drug efficacy for cognitive deficits in schizophrenia.

Authors:  Jim J Hagan; Declan N C Jones
Journal:  Schizophr Bull       Date:  2005-09-21       Impact factor: 9.306

6.  Randomized trial of general hospital and residential alternative care for patients with severe and persistent mental illness.

Authors:  W S Fenton; L R Mosher; J M Herrell; C R Blyler
Journal:  Am J Psychiatry       Date:  1998-04       Impact factor: 18.112

7.  Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

Authors:  Stephen R Marder; Wayne Fenton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

Review 8.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Authors:  Michael F Green; Keith H Nuechterlein; James M Gold; Deanna M Barch; Jonathan Cohen; Susan Essock; Wayne S Fenton; Fred Frese; Terry E Goldberg; Robert K Heaton; Richard S E Keefe; Robert S Kern; Helena Kraemer; Ellen Stover; Daniel R Weinberger; Steven Zalcman; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2004-09-01       Impact factor: 13.382

9.  Risk factors for spontaneous dyskinesia in schizophrenia.

Authors:  W S Fenton; R J Wyatt; T H McGlashan
Journal:  Arch Gen Psychiatry       Date:  1994-08

Review 10.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.